FDA Approves Inebilizumab (Uplizna) for Antibody-Positive Generalized Myasthenia Gravis: Interpreting the MINT Trial and Clinical Implications
The FDA has approved inebilizumab-cdon (Uplizna) for adults with AChR- or MuSK-antibody positive generalized myasthenia gravis based on the phase 3 MINT trial showing a 1.9-point MG‑ADL improvement at 26 weeks versus placebo and sustained benefit in AChR+ patients through 52 weeks.
